Phase 3 Study of Oral Therapy for ‘Off’ Episodes in Parkinson’s Now Enrolling Patients
Cynapsus Therapeutics recently provided an update on APL-130277, its sublingual formulation of apomorphine hydrochloride or apomorphine. Apomorphine injection is the only treatment approved for acute, intermittent “off” episodes in advanced Parkinson’s disease (PD) patients. Motor symptoms such as tremor at rest, rigidity, and impaired movement or freezing, as well as difficulties with starting…